Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells

Pharmazie

Volumn 71, Issue 5, 2016, Pages 274-279

  Lee, Yun Hee ^a   Yun, Jaesuk ^b   Jung, Jae Chul ^c   Oh, Seikwan ^c   Jung, Young Suk ^d  

^a Yonsei University   (South Korea)

^b National Institute of Food and Drug Safety Evaluation   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; PROTEASOME; (2E)-3-(4-HYDROXY-3-METHOXYPHENYL) PHENYLPRO-2-1-ONE; CHALCONE; PROPIOPHENONE DERIVATIVE; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; MALE; PROSTATE CANCER; CHEMISTRY; DIMERIZATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHALCONE; DIMERIZATION; HUMANS; MALE; PROPIOPHENONES; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84973326483     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2016.5845     Document Type: Article

References (34)

1. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P (2006) A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol Pharmacol 70: 426-433.
2. Akihisa T, Tokuda H, Hasegawa D, Ukiya M, Kimura Y, Enjo F, Suzuki T, Nishino H (2006) Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J Nat Prod 69: 38-42.
3. An B, Goldfarb RH, Siman R, Dou QP (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062-1075.
4. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308.
5. Bonfili L, Cecarini V, Amici M, Cuccioloni M, Angeletti M, Keller JN, Eleuteri AM (2008) Natural polyphenols as proteasome modulators and their role as anti-cancer compounds. FEBS J 275: 5512-5526.
6. Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17: 7151-7160.
7. Cuccioloni M, Mozzicafreddo M, Bonfili L, Cecarini V, Eleuteri AM, Angeletti M (2009) Natural occurring polyphenols as template for drug design. Focus on serine proteases. Chem Biol Drug Des 74: 1-15.
8. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874.
9. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281: 1309-1312.
10. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ (1999) Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163.
11. Isaacs JT (2000) Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 92: 1367-1369.
12. Jang S, Jung JC, Kim DH, Ryu JH, Lee Y, Jung M, Oh S (2009) The neuroprotective effects of benzylideneacetophenone derivatives on excitotoxicity and inflammation via phosphorylated Janus tyrosine kinase 2/phosphorylated signal transducer and activator of transcription 3 and mitogen-activated protein K pathways. J Pharmacol Exp Ther 328: 435-447.
13. Jing H, Zhou X, Dong X, Cao J, Zhu H, Lou J, Hu Y, He Q, Yang B (2010) Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett 294: 167-177.
14. Khan N, Afaq F, Mukhtar H (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510.
15. Kim NY, Pae HO, Oh GS, Kang TH, Kim YC, Rhew HY, Chung HT (2001) Butein, a plant polyphenol, induces apoptosis concomitant with increased caspase-3 activity, decreased Bcl-2 expression and increased Bax expression in HL-60 cells. Pharmacol Toxicol 88: 261-266.
16. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP (2006) The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9: 263-273.
17. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA (2000) Complete androgen blockade for prostate cancer: what went wrong? J Urol 164: 3-9.
18. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347.
19. Lopes UG, Erhardt P, Yao R, Cooper GM (1997) p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896.
20. Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789.
21. McBride A, Klaus JO, Stockerl-Goldstein K (2015) Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm 72: 353-360.
22. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP (2008) Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68: 7283-7292.
23. Moul JW, Dawson N (2012) Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest 30: 1-12.
24. Mozzicafreddo M, Cuccioloni M, Bonfili L, Eleuteri AM, Fioretti E, Angeletti M (2008) Antiplasmin activity of natural occurring polyphenols. Biochim Biophys Acta 1784: 995-1001.
25. Nagata S (1997) Apoptosis by death factor. Cell 88: 355-365.
26. Nishimura R, Tabata K, Arakawa M, Ito Y, Kimura Y, Akihisa T, Nagai H, Sakuma A, Kohno H, Suzuki T (2007) Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol Pharm Bull 30: 1878-1883.
27. Oh S, Jang S, Kim D, Han IO, Jung JC (2006) Synthesis and evaluation of biological properties of benzylideneacetophenone derivatives. Arch Pharm Res 29: 469-475.
28. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58: 4342-4348.
29. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
30. Roy M, Chakraborty S, Siddiqi M, Bhattacharya RK (2002) Induction of Apoptosis in Tumor Cells by Natural Phenolic Compounds. Asian Pac J Cancer Prev 3: 61-67.
31. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W (1995) Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268: 579-582.
32. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
33. Steller H (1995) Mechanisms and genes of cellular suicide. Science 267: 1445-1449.
34. Ye CL, Qian F, Wei DZ, Lu YH, Liu JW (2005) Induction of apoptosis in K562 human leukemia cells by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone. Leuk Res 29: 887-892.